Palatin Technologies Inc (NYSE MKT:PTN) — Market Cap & Net Worth
Market Cap & Net Worth: Palatin Technologies Inc (PTN)
Palatin Technologies Inc (NYSE MKT:PTN) has a market capitalization of $2.45 Million ($2.45 Million) as of September 16, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #29860 globally and #6085 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Palatin Technologies Inc's stock price $23.00 by its total outstanding shares 26005800 (26.01 Million). Also see PTN asset base for a full breakdown of the balance sheet.
Palatin Technologies Inc Market Cap History: 2015 to 2025
Palatin Technologies Inc's market capitalization history from 2015 to 2025. Data shows growth from $431.70 Million to $598.13 Million (0.67% CAGR). Also see Palatin Technologies Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Palatin Technologies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Palatin Technologies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Palatin Technologies Inc (PTN) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6.43x
Palatin Technologies Inc's market cap is 6.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $431.70 Million | $12.95 Million | -$17.67 Million | 33.33x | N/A |
| 2017 | $558.41 Million | $44.72 Million | -$13.33 Million | 12.49x | N/A |
| 2018 | $460.56 Million | $67.13 Million | $24.70 Million | 6.86x | 18.64x |
| 2019 | $508.54 Million | $60.30 Million | $35.77 Million | 8.43x | 14.22x |
| 2020 | $439.37 Million | $117.99K | -$22.38 Million | 3723.80x | N/A |
| 2021 | $332.61 Million | $-188.60K | -$33.57 Million | -1763.62x | N/A |
| 2022 | $66.57 Million | $1.47 Million | -$35.81 Million | 45.34x | N/A |
| 2023 | $103.50 Million | $4.85 Million | -$27.54 Million | 21.32x | N/A |
| 2024 | $28.87 Million | $4.49 Million | -$29.74 Million | 6.43x | N/A |
Competitor Companies of PTN by Market Capitalization
Companies near Palatin Technologies Inc in the global market cap rankings as of September 16, 2026. Review Palatin Technologies Inc (PTN) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Palatin Technologies Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Palatin Technologies Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Palatin Technologies Inc's market cap moved from $431.70 Million to $ 598.13 Million, with a yearly change of 0.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $598.13 Million | +1972.07% |
| 2024 | $28.87 Million | -72.11% |
| 2023 | $103.50 Million | +55.47% |
| 2022 | $66.57 Million | -79.98% |
| 2021 | $332.61 Million | -24.30% |
| 2020 | $439.37 Million | -13.60% |
| 2019 | $508.54 Million | +10.42% |
| 2018 | $460.56 Million | -17.52% |
| 2017 | $558.41 Million | +70.05% |
| 2016 | $328.39 Million | -23.93% |
| 2015 | $431.70 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Palatin Technologies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.45 Million USD |
| MoneyControl | $2.45 Million USD |
| MarketWatch | $2.45 Million USD |
| marketcap.company | $2.45 Million USD |
| Reuters | $2.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more